How small decisions lead to massive breakthroughs




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: How small decisions lead to massive breakthroughs
Released on: June 09, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Andreas Barner, Chairman to the Board of Managing Directors to Boehringer Ingelheim, discusses the dramatic changes taking place in BI’s portfolio in recent years, including their forays into new areas of medical need including diabetes, and the successes of Pradaxa© and Praxbind©.
  • Summary
  • Transcript
  • Participants
  • Company
Andreas Barner, Chairman to the Board of Managing Directors to Boehringer Ingelheim, discusses the dramatic changes taking place in BI’s portfolio in recent years, including their forays into new areas of medical need including diabetes, and the successes of Pradaxa© and Praxbind©.
Andreas Barner, Chairman to the Board of Managing Directors to Boehringer Ingelheim, discusses the dramatic changes taking place in BI’s portfolio in recent years, including their forays into new areas of medical need including diabetes, and the successes of Pradaxa© and Praxbind©.
Andreas Barner
Boehringer Ingelheim
Boehringer Ingelheim GmbH is a pharmaceutical company which concentrates on the development of human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products. The Human Pharmaceuticals sector is the company's largest division, accounting for about 96% of sales. This includes prescription medicines and consumer healthcare products.